AIDS 2012: Long-acting HIV Integrase Inhibitor S/GSK1265744 May Allow Monthly Dosing
- Details
- Category: HIV Treatment
- Published on Tuesday, 07 August 2012 00:00
- Written by Liz Highleyman
A nano-suspension formulation of the next-generation integrase inhibitor S/GSK1265744 demonstrated a half-life 21 to 50 days after a single injection, suggesting that once-monthly or even less frequent dosing may be possible, according to a poster presentation at the XIX International AIDS Conference (AIDS 2012) recently held in Washington, DC.
AIDS 2012: French Cohort Treated during Primary Infection Appears to Control HIV without ART
- Details
- Category: Search for a Cure
- Published on Tuesday, 07 August 2012 00:00
- Written by Liz Highleyman
A group of French HIV patients known as the VISCONTI cohort, who started antiretroviral therapy (ART) during the earliest stage of infection, so far appear to be controlling the virus after interrupting treatment, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.
AIDS 2012: HDAC Vorinostat Disrupts HIV Latency in Patients' CD4 Cells
- Details
- Category: Search for a Cure
- Published on Friday, 03 August 2012 00:00
- Written by Liz Highleyman
The histone deacetylase inhibitor vorinostat can interfere with a mechanisms that allows HIV to remain latent in resting CD4 T-cells, offering the potential to flush out the virus -- one approach being explored as a potential cure for HIV, researchers reported in the July 25, 2012, issue of Nature and at the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC.
New Guidance Addresses Expanded Antiretroviral Treatment, Perinatal ART, PrEP
- Details
- Category: HIV Treatment
- Published on Friday, 03 August 2012 00:00
- Written by Liz Highleyman
On the occasion of the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC, the International Antiviral Society-USA (IAS-USA) released new guidelines recommending that all people diagnosed with HIV should be offered antiretroviral therapy (ART).
AIDS 2012: HIV Drugs Cheaper than Thought, Clinton Report Says
- Details
- Category: HIV Treatment
- Published on Friday, 03 August 2012 00:00
- Written by Press Release
Antiretroviral therapy and related care for people with HIV worldwide would likely cost about 4 times less than previously estimated, meaning that wider global scale-up of treatment is possible, according to a new report by the Clinton Health Access Initiative released ahead of the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC. 
More Articles...
- AIDS 2012: Switching from Protease Inhibitor to Complera Maintains Viral Suppression, Lowers Lipids
- AIDS 2012: NIH to Test Dapivirine Vaginal Ring for HIV Prevention
- AIDS 2012: Is Sexually Transmitted Hepatitis C among HIV+ Gay Men Leveling Off in Amsterdam?
- AIDS 2012: HIV PrEP: Toxic Lifelong Therapy or Effective Niche Prevention? [VIDEO]
Web Design and Development by